---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045073"
form_type: "8-K"
ticker: "PTGX"
cik: "0001377121"
company_name: "Protagonist Therapeutics, Inc"
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:19:25.942200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1

## Summary
- Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.
- Rusfertide Phase 3 VERIFY in PV met primary endpoint (p<0.0001) and all 4 key secondaries; ASCO plenary June 1, conf call June 2.
- Icotrokinra Phase 3 ICONIC-LEAD data presented at AAD and WCPD; Phase 2b ANTHEM-UC positive, full data later in 2025.
- Revenue $28.3M includes $22.8M rusfertide milestone recognition; vs $255M Q1 2024 with Takeda upfront.
- Pipeline: oral IL-17 antagonist PN-881 to enter clinic in 2025; cash runway through at least end of 2028.

## SEC filing metadata
- accession: 0001104659-25-045073
- form_type: 8-K
- ticker: PTGX
- cik: 0001377121
- company_name: Protagonist Therapeutics, Inc
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/0001104659-25-045073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/tm2514117d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045073
- JSON: https://secwatch.observer/filing/0001104659-25-045073.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.